drugset / Trial / NCT01256086
Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg
Phase 2
Completed
44 enrolled
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH · collabNuCara Pharmacy, Waterloo, USA · collabProf. Hochhaus, Gainesville, USA · collabTrio Clinical Research, LLC, Raleigh, USA · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to estimate the relative potency for bronchoprotective effect of formoterol Novolizer 12 µg (test) compared to formoterol Aerolizer 12 µg (reference).
Timeline
- Start
- 2010-12
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Formoterol | Other / unclassified | 12 ug | — |
| Subject | Formoterol | Other / unclassified | 24 ug | — |